Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.

[1]  R. Motzer,et al.  Phase I trial sunitinib plus everolimus in patients with metastatic renal cell carcinoma (mRCC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Figlin,et al.  Sequential use of targeted agents in the treatment of renal cell carcinoma. , 2011, Critical reviews in oncology/hematology.

[3]  J. Hainsworth,et al.  Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Sternberg,et al.  Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Soria,et al.  Antiangiogenic agents and late anastomotic complications , 2010, Journal of surgical oncology.

[6]  Michael B Atkins,et al.  Resistance to targeted therapy in renal-cell carcinoma. , 2009, The Lancet. Oncology.

[7]  G. Wilding,et al.  Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Helen X. Chen,et al.  Adverse effects of anticancer agents that target the VEGF pathway , 2009, Nature Reviews Clinical Oncology.

[9]  S. Oudard,et al.  Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. , 2009, European urology.

[10]  W. Kaelin.  Treatment of kidney cancer , 2009, Cancer.

[11]  J. Soria,et al.  From theoretical synergy to clinical supra-additive toxicity. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Motzer,et al.  Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Daniel J Sargent,et al.  Alternate Endpoints for Screening Phase II Studies , 2009, Clinical Cancer Research.

[14]  Larry Rubinstein,et al.  Randomized Phase II Designs , 2009, Clinical Cancer Research.

[15]  R. Motzer,et al.  Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. , 2008, Clinical genitourinary cancer.

[16]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[17]  M. Michaelson,et al.  Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[19]  J. Hainsworth,et al.  Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC) , 2008 .

[20]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[21]  R. Figlin,et al.  Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Jeffrey W. Clark,et al.  Targeted Agents: The Rules of Combination , 2007, Clinical Cancer Research.

[23]  H. Pitot,et al.  Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results , 2007 .

[24]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[25]  M. Atkins,et al.  Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer , 2007, Clinical Cancer Research.

[26]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[27]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[28]  Daohai Yu,et al.  Preliminary results of a phase I study of bevacizumab (BV) in combination with everolimus (E) in patients with advanced solid tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Wilt,et al.  Immunotherapy for advanced renal cell cancer. , 2015, The Cochrane database of systematic reviews.

[30]  Boris Freidlin,et al.  Design issues of randomized phase II trials and a proposal for phase II screening trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Dongsheng Tu,et al.  Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval , 2005, Clinical Cancer Research.

[32]  W. Rathmell,et al.  Renal cell carcinoma , 2007, Current opinion in oncology.

[33]  W. Kaelin,et al.  The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. , 2003, The New England journal of medicine.

[34]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[36]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[37]  M Schemper,et al.  A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.

[38]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[39]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .